Cerus Corporation ((CERS)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Cerus Corporation is conducting an open-label, controlled Phase 2 study titled Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs. The study aims to assess whether transfusing INTERCEPT RBCs into patients with pre-existing antibodies will increase antibody titers, indicating a secondary immune response, and whether these responses are linked to adverse events, increased RBC clearance, or hemolysis. The study also seeks to evaluate the recovery and survival of INTERCEPT RBCs in patients with various diseases.
Intervention/Treatment: The study tests the INTERCEPT RBCs, a device used for transfusion of fresh allogeneic red blood cells, aiming to reduce pathogens and improve transfusion safety.
Study Design: This interventional study is non-randomized with a parallel assignment model. It involves no masking and primarily focuses on screening. Participants are divided into two groups: those with antibodies to INTERCEPT RBCs and those without.
Study Timeline: The study is not yet recruiting as of the last update on August 26, 2025. The study was first submitted on the same date. Key dates for primary and estimated completion are yet to be determined.
Market Implications: The study’s progress could influence Cerus Corporation’s stock performance and investor sentiment, especially if the results demonstrate improved safety and efficacy of INTERCEPT RBCs. This could position Cerus favorably against competitors in the transfusion medicine market.
The study is ongoing, with further details available on the ClinicalTrials portal.